David Gallardo

Has grant

Associate professor

Universitat Autònoma de Barcelona Facultat de Medicina

Spain

Research Interests

Explore related searches

Professors in Spain Professors in Immunology Immunology professors in Spain

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

David Gallardo is an Associate Professor at Universitat de Girona Facultat de Medicina in Spain. His research focuses on the genetic determinants of clinical outcomes in hematological malignancies, particularly in relation to stem cell transplantation and acute myeloid leukemia. Recent studies include investigations into the impact of genetic variants on thymopoiesis and multiple myeloma, as well as the assessment of risk factors for complications post-transplantation.

Recent Grants

Grant: Close

Genotype of immune response inhibitory molecules: beyond allogeneic transplantation. National DNA Bank of patients treated with CAR-T cell therapy.

Open Date: 2021-01-01

Close Date: 2023-12-01

Grant: Close

Modulación de respuesta inmune en trasplante alogénico de progenitores hematopoyéticos por el genotipo de moléculas inhibidoras de checkpoint. Biobanco español de aloTPH

Open Date: 2018-01-01

Close Date: 2020-12-31

Grant: Close

Modulación de respuesta aloinmune frente a antígenos menores de histocompatibilidad por el genotipo de moléculas coestimuladoras y coinhinbidoras. Biobanco español de aloTPH

Open Date: 2015-01-01

Close Date: 2017-12-31

Grant: Close

Minor histocompatibility antigens as mediators of immune alloreactivity in human transplantation

Open Date: 2013-01-01

Close Date: 2015-12-01

Grant: Close

Biobanco de aloTPH del GETH. Polimorfismos en antígenos menores de histocompatibilidad y genes moduladores de respuesta inmune como predictores de alorreactividad

Open Date: 2012-01-01

Close Date: 2014-12-01

Articles (12)

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2020

Year:

2020

Collaborators (2)

Piotr Łacina

Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences

POLAND

View details

Albert Oriol

Institut Català d'Oncologia

SPAIN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

David Gallardo

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (12)

Donor genetic determinant of thymopoiesis, rs2204985, and stem cell transplantation outcome in a multipopulation cohort

CD200 genotype is associated with clinical outcome of patients with multiple myeloma.

Genetic variants of CTLA4 are associated with clinical outcome of patients with multiple myeloma

LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors.

Front-line fludarabine-cyclophosphamide-rituximab (FCR) in 110 patients with chronic lymphocytic leukaemia (CLL): real-life experience with long-term outcomes, toxicities and responses to second-line therapies.

Association between gene polymorphisms in the cyclophosphamide metabolism pathway with complications after haploidentical hematopoietic stem cell transplantation.

5'-nucleotidase, cytosolic II genotype, and clinical outcome in patients with acute myeloid leukemia with intermediate-risk cytogenetics.

Risk prediction of CMV reactivation after allogeneic stem cell transplantation using five non-HLA immunogenetic polymorphisms.

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.

Genetic characterization of acute myeloid leukemia patients with mutations in IDH1/2 genes

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis

UGT1A1 genotype influences clinical outcome in patients with intermediate-risk acute myeloid leukemia treated with cytarabine-based chemotherapy

Collaborators (2)

Piotr Łacina

Albert Oriol

Make your next move.